Gilead Sciences, Inc. (Nasdaq: GILD) announces that it has entered into a definitive agreement to acquire Arcellx (Nasdaq: ACLX) for $115 per share in cash at closing and one contingent value right of $5 per share, which represents an implied equity value of $7.8 billion payable at closing. Arcellx is a biotechnology company focused on delivering a new class of innovative immunotherapies for patients with cancer and other incurable diseases. Kite, a Gilead company, and Arcellx have an existing collaboration to co-develop and co-commercialize Arcellx’s lead pipeline candidate, anitocabtagene autoleucel (anito-cel), an investigational BCMA-directed CAR T-cell therapy for patients with multiple myeloma.
Read the full article: Gilead Sciences to Acquire Arcellx to Maximize Long-Term Potential of Anito-cel //
Source: https://www.businesswire.com/news/home/20260223744889/en/Gilead-Sciences-to-Acquire-Arcellx-to-Maximize-Long-term-Potential-of-Anito-cel